Tokai Pharmaceuticals Inc. (TKAI) Stock Price Down 0.9%
Shares of Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) dropped 0.9% on Friday . The stock traded as low as $5.39 and last traded at $5.47, with a volume of 55,727 shares trading hands. The stock had previously closed at $5.52.
TKAI has been the topic of several analyst reports. BMO Capital Markets initiated coverage on shares of Tokai Pharmaceuticals in a report on Monday, April 11th. They issued an “outperform” rating and a $11.00 target price on the stock. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $12.00 target price on shares of Tokai Pharmaceuticals in a report on Tuesday, April 12th. Finally, Bank of America Corp. initiated coverage on shares of Tokai Pharmaceuticals in a report on Wednesday, April 6th. They issued a “buy” rating and a $16.00 target price on the stock. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $18.00.
The stock’s market cap is $121.78 million. The company has a 50 day moving average of $6.32 and a 200 day moving average of $6.54.
Tokai Pharmaceuticals (NASDAQ:TKAI) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.01. On average, equities research analysts expect that Tokai Pharmaceuticals Inc. will post ($2.00) earnings per share for the current fiscal year.
Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.